| Literature DB >> 25797948 |
Mitsukazu Gotoh1,2, Hiroaki Miyata3,4, Hideki Hashimoto3,4, Go Wakabayashi4, Hiroyuki Konno3,4, Shuichi Miyakawa5, Kenichi Sugihara3, Masaki Mori3, Susumu Satomi3, Norihiro Kokudo3, Tadashi Iwanaka3.
Abstract
The National Clinical Database (NCD) of Japan was established in April, 2010 with ten surgical subspecialty societies on the platform of the Japan Surgical Society. Registrations began in 2011 and over 4,000,000 cases from more than 4100 facilities were registered over a 3-year period. The gastroenterological section of the NCD collaborates with the American College of Surgeons' National Surgical Quality Improvement Program, which shares a similar goal of developing a standardized surgical database for surgical quality improvement, with similar variables for risk adjustment. Risk models of mortality for eight procedures; namely, esophagectomy, partial/total gastrectomy, right hemicolectomy, low anterior resection, hepatectomy, pancreaticoduodenectomy, and surgery for acute diffuse peritonitis, have been established, and feedback reports to participants will be implemented. The outcome measures of this study were 30-day mortality and operative mortality. In this review, we examine the eight risk models, compare the procedural outcomes, outline the feedback reporting, and discuss the future evolution of the NCD.Entities:
Keywords: Gastrointestinal surgery; Mortality; National Clinical Database; Nationwide web-based database; Risk model
Year: 2015 PMID: 25797948 PMCID: PMC4674525 DOI: 10.1007/s00595-015-1146-y
Source DB: PubMed Journal: Surg Today ISSN: 0941-1291 Impact factor: 2.549
Registered cases used to create risk models for 8 surgical procedures [6–13]
| Eso | TG | DG | RHC | LAR | Hx | PD | ADP | |
|---|---|---|---|---|---|---|---|---|
| Registered cases | 5354 | 20,011 | 33,917 | 19,070 | 16,695 | 7732 | 8575 | 8482 |
| Participating hospitals | 713 | 1623 | 1737 | 1689 | 1620 | 987 | 1167 | 1285 |
| (%) | 34.9 | 79.4 | 84.9 | 82.6 | 79.2 | 48.3 | 57.1 | 62.8 |
| 30-day mortality (%) | 1.2 | 0.9 | 0.5 | 1.1 | 0.4 | 2.0 | 1.2 | 9.0 |
| Operative mortality (%) | 3.4 | 2.3 | 1.2 | 2.3 | 0.9 | 4.0 | 2.8 | 14.1 |
| Cancer surgery (%) | 98.4 | 98.5 | 99.9 | 92.6 | 98.5 | 94.5 | 91.4 | 10.8 |
| Emergent case (%) | 0.8 | 2.0 | 0.9 | 8.4 | 1.1 | 0.8 | 0.9 | 92.9 |
Esophagectomy (Eso), total/distal gastrectomy (TG/DG), right hemicolectomy (RHC), low anterior resection (LAR), hepatectomy performed for >1 segment except for the lateral segment (Hx), pancreaticoduodenectomy (PD), and operation for acute diffuse peritonitis (ADP)
Risk models for 30-day mortality after 8 gastrointestinal procedures (refs 6–13)
| Variables | Eso | TG | DG | RHC | LAR | Hx | PD | ADP |
|---|---|---|---|---|---|---|---|---|
| Age category | 1.5 | 1.2 | 1.2 | 1.3 | 1.4 | 1.3 | 1.2 | |
| Male sex | 1.6 | 2.0 | ||||||
| Ambulance transport | 1.4 | |||||||
| Emergent surgery | 1.9 | 3.8 | 4.3 | |||||
| ADL within 30 days before surgery | ||||||||
| Any assistance | 4.2 | 2.1 | ||||||
| Total | 3.0 | |||||||
| ADL immediately before surgery | ||||||||
| Any assistance | 2.1 | 2.8 | ||||||
| Total | 1.4 | |||||||
| ASA | ||||||||
| Class 3 | 2.3 | 2.7 | ||||||
| Class 4 | 4.3 | |||||||
| Class 5 | 8.7 | |||||||
| Class 3, 4, 5 | 2.0 | 2.0 | 2.2 | |||||
| Class 4, 5 | 9.4 | 4.0 | ||||||
| BMI | ||||||||
| >25 kg/m2 | 2.4 | |||||||
| >30 kg/m2 | 7.0 | |||||||
| Congestive heart failure | 2.3 | |||||||
| Previous cardiac surgery | 2.3 | |||||||
| Myocardial infarction | 3.1 | |||||||
| Previous PCI | 2.0 | |||||||
| Previous PVD surgery | 6.2 | 2.5 | ||||||
| Cerebrovascular disease | 2.1 | |||||||
| COPD | 2.4 | |||||||
| Preoperative pneumonia | 2.8 | |||||||
| Respiratory distress | 1.6 | |||||||
| Acute renal failure | 3.2 | |||||||
| Preoperative dialysis | 3.9 | |||||||
| Cancer with multiple metastases | 2.2 | |||||||
| Disseminated cancer | 2.6 | 4.9 | 2.2 | |||||
| Preoperative transfusion | 1.9 | 5.4 | 1.6 | |||||
| Bleeding disorder without treatment | 3.2 | 5.2 | 1.6 | |||||
| Bleeding disorder | 4.4 | |||||||
| Diabetes | 2.2 | |||||||
| Smoking within 1 year | 2.6 | |||||||
| Ascites | 2.0 | 2.1 | ||||||
| Without control | 3.0 | |||||||
| Chronic steroid use | 1.7 | |||||||
| Weight loss | 2.4 | 2.3 | ||||||
| Sepsis | 2.0 | |||||||
| Habitual alcohol consumption | 1.6 | |||||||
| WBC | ||||||||
| >12,000/μl | 3.7 | 3.7 | ||||||
| >9000/μl | 1.5 | |||||||
| <4000/μl | 2.8 | 1.4 | ||||||
| Hemoglobin | ||||||||
| M < 13.5 g/dl, F < 12.5 g/dl | 1.7 | 1.8 | ||||||
| <10.0 g/dl | 1.3 | |||||||
| Platelet | ||||||||
| >400,000/μl | 2.5 | |||||||
| <150,000/μl | 1.5 | |||||||
| <120,000/μl | 1.9 | 5.0 | 1.7 | |||||
| <80,000/μl | 3.1 | 1.5 | ||||||
| <50,000/μl | 5.6 | |||||||
| Albumin | ||||||||
| <4.0 g/dl | 2.0 | 3.4 | ||||||
| <3.5 g/dl | 1.7 | 1.5 | 2.0 | |||||
| <2.0 g/dl | 1.7 | |||||||
| Total bilirubin | ||||||||
| >3.0 mg/dl | 3.1 | 1.7 | ||||||
| >2.0 mg/dl | 2.9 | |||||||
| AST | ||||||||
| >35 U/l | 2.3 | 3.1 | 2.3 | 1.4 | ||||
| ALP | ||||||||
| >600 U/l | 2.5 | 1.7 | ||||||
| >340 U/l | 1.7 | 2.2 | ||||||
| BUN | ||||||||
| >25 mg/dl | 1.9 | 2.5 | 1.4 | |||||
| >20 mg/dl | 1.8 | |||||||
| <8.0 mg/dl | 2.3 | |||||||
| Creatinine | ||||||||
| >2.0 mg/dl | 3.9 | |||||||
| >1.2 mg/dl | 1.8 | |||||||
| Serum Na | ||||||||
| >145 mEq/l | 1.7 | |||||||
| <138 mEq/l | 2.1 | 3.6 | ||||||
| <135 mEq/l | 3.6 | 2.5 | ||||||
| <130 mEq/l | 1.7 | |||||||
| CRP | ||||||||
| <10.0 mg/dl | 1.5 | |||||||
| APTT | ||||||||
| >40 s | 3.2 | |||||||
| PT-INR | ||||||||
| >1.25 | 2.2 | 2.0 | ||||||
| >1.1 | 2.0 | 1.5 | 1.7 | |||||
| Non-tumor bearing | 0.6 | |||||||
| Surgical procedures | #1 | |||||||
| Indication for surgery | #2 | |||||||
#1 Hepatectomy with S8 (2.2), hepatectomy with revascularization (3.8)
#2 Hilar bile duct carcinoma (2.5), gallbladder cancer (4.1)
ADL, Activities of daily living, PT-INR Prothrombin time-international normalized ratio, WBC white blood cells, ASA American society of anesthesiologists, ADL activities of daily living, PCI percutaneous coronary intervention, COPD chronic obstructive pulmonary disease, AST aspartate amino transferase, ALP alkaline phosphatase, APTT activated partial thromboplastin time
Risk models for operative mortality after 8 gastrointestinal procedures [6–13]
| Variables | Eso | TG | DG | RHC | LAR | Hx | PD | ADP |
|---|---|---|---|---|---|---|---|---|
| Age category | 1.4 | 1.3 | 1.3 | 1.1 | 1.4 | 1.4 | 1.3 | 1.3 |
| Male sex | 2.3 | 1.9 | 1.5 | |||||
| Emergent surgery | 1.7 | 1.9 | 1.9 | 2.8 | ||||
| ADL within 30 days before surgery | ||||||||
| Any assistance | 4.7 | 2.8 | 2.5 | |||||
| Total | 1.6 | |||||||
| ADL immediately before surgery | ||||||||
| Any assistance | 2.0 | 2.5 | 2.5 | 1.4 | ||||
| Total | 3.0 | 2.9 | ||||||
| ASA | ||||||||
| Class 3 | 1.8 | 1.6 | 2.3 | |||||
| Class 4 | 4.7 | |||||||
| Class 5 | 6.5 | |||||||
| Class 3, 4, 5 | 1.9 | 2.0 | 2.1 | |||||
| Class 4, 5 | 5.2 | 2.9 | ||||||
| BMI | ||||||||
| >25 kg/m2 | 1.9 | |||||||
| >30 kg/m2 | 4.6 | |||||||
| Congestive heart failure | 2.2 | |||||||
| Angina | 2.6 | |||||||
| Previous PVD surgery | 3.1 | 5.8 | ||||||
| Cerebrovascular disease | 1.8 | |||||||
| Cerebrovascular accident | 1.9 | |||||||
| Respiratory distress | ||||||||
| Any | 1.7 | 2.4 | 2.9 | 2.4 | ||||
| COPD | 2.1 | 2.0 | ||||||
| Preoperative pneumonia | 3.8 | 1.4 | ||||||
| Preoperative dialysis | 2.6 | 2.1 | ||||||
| Cancer metastasis/relapse | 4.5 | 1.6 | ||||||
| Disseminated cancer | 3.5 | 2.9 | 3.1 | 2.8 | 2.1 | |||
| Preoperative transfusion | 2.6 | 1.8 | ||||||
| Bleeding disorder without therapy | 1.6 | |||||||
| Brinkman index | 1.6 | |||||||
| Ascites | ||||||||
| Any | 1.8 | 1.6 | 4.0 | 1.9 | ||||
| Without control | 2.8 | |||||||
| Chronic steroid use | 2.8 | 2.0 | 1.9 | |||||
| Weight loss | 2.0 | 1.6 | 2.2 | 1.6 | 2.1 | 1.4 | ||
| Sepsis | 1.7 | |||||||
| WBC | ||||||||
| >11,000/μl | 2.0 | 2.5 | 3.1 | |||||
| >9000/μl | 1.6 | |||||||
| <4500/μl | 1.8 | 1.5 | ||||||
| <3500/μl | 1.6 | |||||||
| Hemoglobin | ||||||||
| M < 13.5 g/dl, F < 12.5 g/dl | 2.6 | 1.3 | ||||||
| <10 g/dl | 1.8 | |||||||
| Hematocrit | ||||||||
| M > 48 %, F > 42 % | 3.6 | |||||||
| M < 37 %, F < 32 % | 1.4 | 1.4 | ||||||
| <30 % | 1.3 | 1.2 | ||||||
| Platelet | ||||||||
| <120,000/μl | 2.0 | 2.0 | 1.7 | 3.4 | 1.6 | 2.1 | 1.4 | |
| <80,000/μl | 2.6 | 2.1 | ||||||
| Albumin | ||||||||
| <3.8 g/dl | 1.7 | |||||||
| <3.5 g/dl | 2.2 | 1.4 | 1.6 | |||||
| <3.0 g/dl | 1.4 | 1.5 | 1.7 | 1.4 | ||||
| <2.5 g/dl | 2.7 | |||||||
| <2.0 g/dl | 1.5 | |||||||
| Total bilirubin | ||||||||
| >3.0 mg/dl | 2.0 | |||||||
| >2.0 mg/dl | 2.8 | 2.6 | ||||||
| >1.0 mg/dl | 1.6 | |||||||
| AST | ||||||||
| >40 U/l | 1.5 | 2.7 | 1.9 | 1.7 | ||||
| >35 U/l | 1.7 | 1.4 | ||||||
| ALP | ||||||||
| >600 U/l | 3.1 | 1.6 | ||||||
| >340 U/l | 1.6 | |||||||
| BUN | ||||||||
| >60 mg/dl | 2.4 | |||||||
| >25 mg/dl | 1.3 | |||||||
| >20 mg/dl | 1.8 | |||||||
| <8 mg/dl | 2.6 | 1.6 | ||||||
| Creatinine | ||||||||
| >2.0 mg/dl | 1.5 | |||||||
| >1.2 mg/dl | 1.8 | |||||||
| Serum Na | ||||||||
| >145 mEq/l | 1.9 | |||||||
| <138 mEq/l | 2.1 | 1.4 | 1.9 | 2.5 | ||||
| <135 mEq/l | 2.3 | |||||||
| <130 mEq/l | 1.8 | |||||||
| CRP | ||||||||
| <10.0 mg/dl | 1.5 | |||||||
| APTT | ||||||||
| >40 s | 1.6 | 2.0 | ||||||
| PT-INR | ||||||||
| >1.25 | 3.0 | 1.9 | ||||||
| >1.1 | 1.5 | 1.4 | 1.4 | 1.5 | ||||
| Non-tumor bearing | 0.5 | |||||||
| Surgical procedure | #1 | #2 | ||||||
| indication for surgery | #3 | |||||||
#1 Pancreatico splenectomy (2.2)
#2 Hepatectomy with S1 (1.6), S7 (1.6), S8 (2.0), left tri-segmentectomy with S1 resection (3.9), hepatectomy with revascularization (3.0)
#3 Intrahepatic cholangiocarcinoma (1.8), hilar bile duct carcinoma (2.0), gallbladder cancer (3.2)
Fig. 1The National Cancer Database feedback system includes a risk calculator for the mortality and morbidity of preoperative patients (left schema) and performance reports of each participating hospital (right schema). The latter includes each facility’s severity-adjusted clinical performance (benchmark) in comparison with the national data (a) and the risk-adjusted cumulative expected–observed death (b). Better (right) or worse (left) outcomes can be detected by the monitoring report